Next Article in Journal
Barriers to the Access of Bevacizumab in Patients with Solid Tumors and the Potential Impact of Biosimilars: A Physician Survey
Next Article in Special Issue
In Search of Small Molecule Inhibitors Targeting the Flexible CK2 Subunit Interface
Previous Article in Journal
“The 24th Conference” of the Groupement des Pharmacochimistes de l’Arc Atlantique (GP2A)
Previous Article in Special Issue
Exploring the CK2 Paradox: Restless, Dangerous, Dispensable
Article Menu
Issue 1 (March) cover image

Export Article

Open AccessReview
Pharmaceuticals 2017, 10(1), 18; doi:10.3390/ph10010018

CK2 in Cancer: Cellular and Biochemical Mechanisms and Potential Therapeutic Target

Department of Medicine, School of Medicine, Boston University, Boston, MA 02118, USA
These authors contributed equally to this work.
*
Author to whom correspondence should be addressed.
Academic Editor: Marc Le Borgne
Received: 2 December 2016 / Revised: 23 January 2017 / Accepted: 23 January 2017 / Published: 28 January 2017
View Full-Text   |   Download PDF [493 KB, uploaded 3 February 2017]   |  

Abstract

CK2 genes are overexpressed in many human cancers, and most often overexpression is associated with worse prognosis. Site-specific expression in mice leads to cancer development (e.g., breast, lymphoma) indicating the oncogenic nature of CK2. CK2 is involved in many key aspects of cancer including inhibition of apoptosis, modulation of signaling pathways, DNA damage response, and cell cycle regulation. A number of CK2 inhibitors are now available and have been shown to have activity against various cancers in vitro and in pre-clinical models. Some of these inhibitors are now undergoing exploration in clinical trials as well. In this review, we will examine some of the major cancers in which CK2 inhibition has promise based on in vitro and pre-clinical studies, the proposed cellular and signaling mechanisms of anti-cancer activity by CK2 inhibitors, and the current or recent clinical trials using CK2 inhibitors. View Full-Text
Keywords: CK2; cancer; proliferation; apoptosis; migration; invasion; signaling pathways; signaling cascades; preclinical models; clinical trials; therapy CK2; cancer; proliferation; apoptosis; migration; invasion; signaling pathways; signaling cascades; preclinical models; clinical trials; therapy
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Chua, M.M.; Ortega, C.E.; Sheikh, A.; Lee, M.; Abdul-Rassoul, H.; Hartshorn, K.L.; Dominguez, I. CK2 in Cancer: Cellular and Biochemical Mechanisms and Potential Therapeutic Target. Pharmaceuticals 2017, 10, 18.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top